Search

DP-b99

DP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment

3,4-Methylenedioxy-N-isopropylamphetamine

HIV is the virus that causes acquired immune deficiency syndrome (AIDS). MDI-P is also a potential therapeutic agent for the treatment of the symptoms of cystic fibrosis ("CF").

Ciluprevir

The compound, named BILN 2061, is an orally active inhibitor of the HCV NS3 protease and the first member of this new drug class to be tested in humans.

MPI-674

MPI-674 is an aromatase inhibitor (AI) with a well-established, multi-year chronic safety and tolerability profile. … AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and inhibiting the enzyme aromatase, which is responsible for converting certain hormones to estrogen.

Tandutinib

The use of MLN518 to treat AML has been granted fast-track status by the U.S. Food and Drug Administration. Phase I/II trials are underway. … MLN518 is a novel, oral, small molecule designed to inhibit type III receptor tyrosine kinases, including FLT3, (platelet-derived growth-factor receptor) PDGFR and c-KIT.

Milveterol

GSK159797 ('797) is an inhaled, longer-acting Beta2 agonist developed for the treatment of respiratory disease such as asthma and COPD.

Tioxolone

GFT14

) and on other risk factors such as hypertension or diabetes. … GFT14 is a new class of medicaction for treatment of cardiometabolic disease.

Lanoteplase

Lobeline

An alkaloid that has actions similar to nicotine on nicotinic cholinergic receptors but is less potent.